Trump announces trade deal with EU following months of negotiations
Investing.com - H.C. Wainwright reduced its price target on SAB Biotherapeutics (NASDAQ:SABS) to $9.00 from $10.00 while maintaining a Buy rating on the stock. The new target represents significant upside from the current trading price of $2.70, though InvestingPro data shows the company faces profitability challenges with negative earnings over the last twelve months.
The price target adjustment comes ahead of the company’s second-quarter 2025 earnings report, which InvestingPro data confirms is scheduled for August 8, 2025. The company holds more cash than debt on its balance sheet, though it has been quickly burning through available funds.
Despite the lower price target, H.C. Wainwright has kept its Buy recommendation on SAB Biotherapeutics shares, indicating continued confidence in the company’s overall outlook.
The analyst note included observations about product development teams and their focus allocation, with approximately one-third of engineering resources directed toward near-term conversions.
App usage metrics were also highlighted in the research note, with data suggesting improvements in global monthly active users and download growth compared to previous quarters.
In other recent news, SAB Biotherapeutics has announced a significant financing deal, securing $175 million through a private placement. This financing round was oversubscribed and included participation from strategic investor Sanofi (NASDAQ:SNY), as well as new investors such as RA Capital Management, Commodore Capital, Vivo Capital, and Blackstone (NYSE:BX) Multi-Asset Investing. Existing investors like Sessa Capital, the T1D Fund, and ATW Partners also contributed to this financing effort. Following this announcement, Oppenheimer raised its price target for SAB Biotherapeutics from $12 to $14, maintaining an Outperform rating on the stock. The financing deal also includes the potential for an additional $284 million through warrants. These recent developments highlight strong investor interest and financial backing for SAB Biotherapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.